產品編號 | bs-8489R-BF594 |
英文名稱1 | Rabbit Anti-FBXO7/BF594 Conjugated antibody |
中文名稱 | BF594標記的F-box蛋白家族FBXO7抗體 |
別 名 | F box only protein 7; F box protein 7; F-box protein 7; FBX; FBX07; FBX7; PARK15; PKPS; |
規格價格 | 100ul/2980元 購買 大包裝/詢價 |
說 明 書 | 100ul |
研究領域 | 細胞生物 免疫學 細胞周期蛋白 表觀遺傳學 泛素 |
抗體來源 | Rabbit |
克隆類型 | Polyclonal |
交叉反應 | |
產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
分 子 量 | 59kDa |
性 狀 | Lyophilized or Liquid |
濃 度 | 1mg/ml |
免 疫 原 | KLH conjugated synthetic peptide derived from human FBXO7 |
亞 型 | IgG |
純化方法 | affinity purified by Protein A |
儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
產品介紹 |
background: FBXO7, also known as FBX, FBX7 or PKPS, is a 522 amino acid protein that contains one F-box domain and functions as a component of the SCF complex. Defects in the gene encoding FBXO7 are associated with parkinsonian-pyramidal syndrome (PKPS), a hypokinetic rigid disorder that exhibits Parkinsonian and pyramidal-associated symptoms.The FBXO7 gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. F-box proteins constitute one of the four subunits of the ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbxs class and it may play a role in regulation of hematopoiesis. Alternatively spliced transcript variants of this gene have been identified with the full-length natures of only some variants being determined. Function: Substrate recognition component of a (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes BIRC2 and DLGAP5. Subunit: Part of the SCF (SKP1-CUL1-F-box) E3 ubiquitin-protein ligase complex SCF(FBXO7) formed of CUL1, SKP1, RBX1 and FBXO7. Interacts via its C-terminal proline-rich region with DLGAP5. Interacts with BIRC2. Interacts with CDK6 and promotes its interaction with D-type cyclin. Subcellular Location: Cytoplasm. Nucleus DISEASE: Defects in FBXO7 are the cause of Parkinson disease type 15 (PARK15) [MIM:260300]; also known as parkinsonian-pyramidal syndrome. A neurodegenerative disorder characterized by parkinsonian and pyramidal signs. Clinical manifestations include tremor, bradykinesia, rigidity, postural instability, spasticity, mainly in the lower limbs, and hyperreflexia. Similarity: Contains 1 F-box domain. Database links: UniProtKB/Swiss-Prot: Q9Y3I1.1 Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
1、抗體溶解方法 | |
2、抗體修復方式 | |
3、常用試劑的配制 | |
4、免疫組化操作步驟 | |
5、免疫組化問題解答 | |
6、Western Blotting 操作步驟 | |
7、Western Blotting 問題解答 | |
8、關于肽鏈的設計 | |
9、多肽的溶解與保存 | |
10、酶標抗體效價測定程序 | |